Pasithea Therapeutics (KTTA) Net Cash Flow (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Net Cash Flow of -$4.8 million for Q1 2026, down 109.38% sequentially from $51.0 million in Q4 2025, and down 202.66% YoY from $4.7 million in Q1 2025.
Pasithea Therapeutics (KTTA) Net Cash Flow (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Net Cash Flow for 6 years, with the latest figure at -$4.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 202.66% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.1 million (up 502.43% YoY) and the FY2025 annual result came in at $48.3 million, up 613.71% from the prior year.
- Net Cash Flow declined to -$4.8 million in Q1 2026 per KTTA's latest filing, from $51.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $51.0 million in Q4 2025 and troughed at -$7.0 million in Q3 2023.
- A 5-year average of -$63868.5 and a median of -$3.1 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 360.45% in 2022, then soared 2168.64% in 2025.
- Over 5 years, Net Cash Flow stood at -$5.5 million in 2022, then jumped by 41.39% to -$3.2 million in 2023, then gained by 23.87% to -$2.5 million in 2024, then jumped by 2168.64% to $51.0 million in 2025, then tumbled by 109.38% to -$4.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$4.8 million, $51.0 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | -4.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | 51.02 Mn |
| Dec 31, 2025 | 51.02 Mn |
| Sep 30, 2025 | -3.01 Mn |
| Sep 30, 2025 | -3.01 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Dec 31, 2023 | -3.24 Mn |
| Dec 31, 2023 | -3.24 Mn |